{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:10:07Z","timestamp":1790442607750,"version":"4.1.0"},"reference-count":118,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003606","name":"Korea Foundation","doi-asserted-by":"publisher","award":["2016R1D1A1B03933100"],"award-info":[{"award-number":["2016R1D1A1B03933100"]}],"id":[{"id":"10.13039\/501100003606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>From its unexpected discovery as a bacterial adaptive immune system to its countless applications as one of the most versatile gene-editing tools, the CRISPR\/Cas9 system has revolutionized every field of life science. Virology is no exception to this ever-growing list of CRISPR\/Cas9-based applications. Direct manipulation of a virus genome by CRISPR\/Cas9 has enabled a systematic study of cis-elements and trans-elements encoded in a virus genome. In addition, this virus genome-specific mutagenesis by CRISPR\/Cas9 was further funneled into the development of a novel class of antiviral therapy targeting many incurable chronic viral infections. In this review, a general concept on the CRISPR\/Cas9-based antiviral strategy will be described first. To understand the current status of the CRISPR\/Cas9-based antiviral approach, a series of recently published antiviral studies involving CRISPR\/Cas9-mediated control of several clinically-relevant viruses including human immunodeficiency virus, hepatitis B virus, herpesviruses, human papillomavirus, and other viruses will be presented. Lastly, the potential challenge and future prospect for successful clinical translation of this CRISPR\/Cas9-based antiviral method will be discussed.<\/jats:p>","DOI":"10.3390\/molecules24071349","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T11:36:01Z","timestamp":1554464161000},"page":"1349","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["CRISPR\/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4630-8428","authenticated-orcid":false,"given":"Choongho","family":"Lee","sequence":"first","affiliation":[{"name":"College of Pharmacy, Dongguk University, Goyang 10326, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrd1151","article-title":"Toxicity of antiretroviral therapy and implications for drug development","volume":"2","author":"Carr","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.omtn.2018.05.021","article-title":"Removal of HIV DNA by CRISPR from patient blood engrafts in humanized mice","volume":"12","author":"Bella","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1038\/srep02510","article-title":"Harnessing the CRISPR\/Cas9 system to disrupt latent HIV-1 provirus","volume":"3","author":"Ebina","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11461","DOI":"10.1073\/pnas.1405186111","article-title":"Rna-directed gene editing specifically eradicates latent and prevents new HIV-1 infection","volume":"111","author":"Hu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/gt.2016.41","article-title":"Excision of HIV-1 DNA by gene editing: A proof-of-concept in vivo study","volume":"23","author":"Kaminski","year":"2016","journal-title":"Gene Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"22555","DOI":"10.1038\/srep22555","article-title":"Elimination of HIV-1 genomes from human t-lymphoid cells by CRISPR\/Cas9 gene editing","volume":"6","author":"Kaminski","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31527","DOI":"10.1038\/srep31527","article-title":"Negative feedback regulation of HIV-1 by gene editing strategy","volume":"6","author":"Kaminski","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1038\/ncomms7413","article-title":"Use of the CRISPR\/Cas9 system as an intracellular defense against HIV-1 infection in human cells","volume":"6","author":"Liao","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.virusres.2018.04.002","article-title":"Genome-scale screening identification of saCas9\/grnas for targeting HIV-1 provirus and suppression of HIV-1 infection","volume":"250","author":"Wang","year":"2018","journal-title":"Virus Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/QAD.0000000000001079","article-title":"Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of aids","volume":"30","author":"Yin","year":"2016","journal-title":"AIDS"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ymthe.2017.03.012","article-title":"In vivo excision of HIV-1 provirus by saCas9 and multiplex single-guide RNAs in animal models","volume":"25","author":"Yin","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12977-015-0150-z","article-title":"The CRISPR\/Cas9 system inactivates latent HIV-1 proviral DNA","volume":"12","author":"Zhu","year":"2015","journal-title":"Retrovirology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.2507","article-title":"Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease","volume":"31","author":"Cho","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1101\/gr.162339.113","article-title":"Analysis of off-target effects of CRISPR\/Cas-derived RNA-guided endonucleases and nickases","volume":"24","author":"Cho","year":"2014","journal-title":"Genome Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.1093\/nar\/gkt714","article-title":"CRISPR\/Cas9 systems targeting beta-globin and ccr5 genes have substantial off-target activity","volume":"41","author":"Cradick","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"15577","DOI":"10.1038\/srep15577","article-title":"Genome editing of cxcr4 by CRISPR\/Cas9 confers cells resistant to HIV-1 infection","volume":"5","author":"Hou","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.celrep.2016.09.080","article-title":"A Cas9 ribonucleoprotein platform for functional genetic studies of HIV-host interactions in primary human t cells","volume":"17","author":"Hultquist","year":"2016","journal-title":"Cell Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1099\/vir.0.000139","article-title":"Inhibition of HIV-1 infection of primary cd4+ t-cells by gene editing of ccr5 using adenovirus-delivered CRISPR\/Cas9","volume":"96","author":"Li","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1038\/s41598-018-26894-4","article-title":"Hiv-1 inhibition in cells with cxcr4 mutant genome created by CRISPR-Cas9 and piggybac recombinant technologies","volume":"8","author":"Liu","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13578-017-0174-2","article-title":"Genome editing of the HIV co-receptors ccr5 and cxcr4 by CRISPR-Cas9 protects cd4(+) t cells from HIV-1 infection","volume":"7","author":"Liu","year":"2017","journal-title":"Cell Biosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12977-017-0375-0","article-title":"Genome modification of cxcr4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection","volume":"14","author":"Wang","year":"2017","journal-title":"Retrovirology"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wang, W., Ye, C., Liu, J., Zhang, D., Kimata, J.T., and Zhou, P. (2014). Ccr5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115987"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.ymthe.2017.04.027","article-title":"CRISPR\/Cas9-mediated ccr5 ablation in human hematopoietic stem\/progenitor cells confers HIV-1 resistance in vivo","volume":"25","author":"Xu","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9591","DOI":"10.1073\/pnas.1407473111","article-title":"Seamless modification of wild-type induced pluripotent stem cells to the natural ccr5delta32 mutation confers resistance to HIV infection","volume":"111","author":"Ye","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/hum.2017.032","article-title":"Simultaneous knockout of cxcr4 and ccr5 genes in CD4+ T cells via CRISPR\/Cas9 confers resistance to both x4- and r5-tropic human immunodeficiency virus type 1 infection","volume":"29","author":"Yu","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s13365-014-0308-9","article-title":"Genome editing strategies: Potential tools for eradicating HIV-1\/aids","volume":"21","author":"Khalili","year":"2015","journal-title":"J. Neurovirol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Darcis, G., Das, A.T., and Berkhout, B. (2018). Tackling HIV persistence: Pharmacological versus CRISPR-based shock strategies. Viruses, 10.","DOI":"10.3390\/v10040157"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bialek, J.K., Dunay, G.A., Voges, M., Schafer, C., Spohn, M., Stucka, R., Hauber, J., and Lange, U.C. (2016). Targeted HIV-1 latency reversal using CRISPR\/Cas9-derived transcriptional activator systems. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158294"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/mt.2015.213","article-title":"CRISPR-mediated activation of latent HIV-1 expression","volume":"24","author":"Limsirichai","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"16277","DOI":"10.1038\/srep16277","article-title":"CRISPR\/gRNA-directed synergistic activation mediator (sam) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/mt.2016.7","article-title":"Specific reactivation of latent HIV-1 by dCas9-Suntag-vp64-mediated guide RNA targeting the HIV-1 promoter","volume":"24","author":"Ji","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/mt.2015.202","article-title":"Potent and targeted activation of latent HIV-1 using the CRISPR\/dCas9 activator complex","volume":"24","author":"Saayman","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"E7249","DOI":"10.1073\/pnas.1516305112","article-title":"Specific induction of endogenous viral restriction factors using CRISPR\/Cas-derived transcriptional activators","volume":"112","author":"Bogerd","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Dufour, C., Claudel, A., Joubarne, N., Merindol, N., Maisonnet, T., Masroori, N., Plourde, M.B., and Berthoux, L. (2018). Editing of the human trim5 gene to introduce mutations with the potential to inhibit HIV-1. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191709"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Teng, Y., Luo, M., Yu, T., Chen, L., Huang, Q., Chen, S., Xie, L., Zeng, Y., Luo, F., and Xiong, H. (2018). CRISPR\/Cas9-mediated deletion of mir-146a enhances antiviral response in HIV-1 infected cells. Genes Immun.","DOI":"10.1038\/s41435-018-0036-x"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/1348-0421.12395","article-title":"Anti-HIV-1 potency of the CRISPR\/Cas9 system insufficient to fully inhibit viral replication","volume":"60","author":"Ueda","year":"2016","journal-title":"Microbiol. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/mt.2016.24","article-title":"CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape","volume":"24","author":"Wang","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.celrep.2016.11.057","article-title":"A combinatorial CRISPR-Cas9 attack on HIV-1 DNA extinguishes all infectious provirus in infected t cell cultures","volume":"17","author":"Wang","year":"2016","journal-title":"Cell Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.celrep.2016.03.042","article-title":"CRISPR\/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape","volume":"15","author":"Wang","year":"2016","journal-title":"Cell Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"29530","DOI":"10.1038\/srep29530","article-title":"Host double-strand break repair generates HIV-1 strains resistant to CRISPR\/Cas9","volume":"6","author":"Yoder","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"41968","DOI":"10.1038\/srep41968","article-title":"A combinational CRISPR\/cas9 gene-editing approach can halt HIV replication and prevent viral escape","volume":"7","author":"Lebbink","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.virol.2018.05.016","article-title":"Insights into the mechanisms underlying the inactivation of HIV-1 proviruses by CRISPR\/Cas","volume":"520","author":"Mefferd","year":"2018","journal-title":"Virology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1128\/JVI.80.3.1067-1076.2006","article-title":"Role and mechanism of action of the apobec3 family of antiretroviral resistance factors","volume":"80","author":"Cullen","year":"2006","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.virol.2005.06.005","article-title":"Human apobec3b is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 vif","volume":"339","author":"Doehle","year":"2005","journal-title":"Virology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.1128\/JVI.00270-06","article-title":"Removal of arginine 332 allows human trim5alpha to bind human immunodeficiency virus capsids and to restrict infection","volume":"80","author":"Li","year":"2006","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1073\/pnas.0409853102","article-title":"Positive selection of primate trim5alpha identifies a critical species-specific retroviral restriction domain","volume":"102","author":"Sawyer","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1089\/hum.2015.059","article-title":"Preclinical assessment of mutant human trim5alpha as an anti-HIV-1 transgene","volume":"26","author":"Jung","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","article-title":"Hepatitis b virus infection","volume":"337","author":"Lee","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis b virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.antiviral.2015.06.014","article-title":"Chronic hepatitis b: A wave of new therapies on the horizon","volume":"121","author":"Block","year":"2015","journal-title":"Antiviral Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1126\/science.1252186","article-title":"Virology. Getting rid of a persistent troublemaker to cure hepatitis","volume":"343","author":"Shlomai","year":"2014","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.13656","article-title":"Towards HBV curative therapies","volume":"38","author":"Schinazi","year":"2018","journal-title":"Liver Int."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Bloom, K., Maepa, M.B., Ely, A., and Arbuthnot, P. (2018). Gene therapy for chronic HBV-can we eliminate cccDNA?. Genes (Basel), 9.","DOI":"10.3390\/genes9040207"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1136\/gutjnl-2016-313565","article-title":"CRISPR\/Cas9: At the cutting edge of hepatology","volume":"66","author":"Pankowicz","year":"2017","journal-title":"Gut"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12250-015-3660-x","article-title":"CRISPR\/Cas9-based tools for targeted genome editing and replication control of HBV","volume":"30","author":"Peng","year":"2015","journal-title":"Virol. Sin."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"26077","DOI":"10.3390\/ijms161125950","article-title":"Application of CRISPR\/Cas9 technology to HBV","volume":"16","author":"Lin","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.virusres.2017.06.010","article-title":"The potential and challenges of CRISPR-Cas in eradication of hepatitis b virus covalently closed circular DNA","volume":"244","author":"Yang","year":"2018","journal-title":"Virus Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.virusres.2017.01.003","article-title":"Advances with using CRISPR\/Cas-mediated gene editing to treat infections with hepatitis b virus and hepatitis c virus","volume":"244","author":"Moyo","year":"2018","journal-title":"Virus Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/mt.2016.43","article-title":"Progress with developing use of gene editing to cure chronic infection with hepatitis b virus","volume":"24","author":"Ely","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.antiviral.2015.10.004","article-title":"Targeting hepatitis b virus cccDNA using CRISPR\/Cas9","volume":"123","author":"Kennedy","year":"2015","journal-title":"Antiviral Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1038\/mtna.2014.68","article-title":"Targeting hepatitis b virus with CRISPR\/Cas9","volume":"3","author":"Seeger","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","article-title":"Targeting hepatitis b virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication","volume":"118","author":"Dong","year":"2015","journal-title":"Antiviral Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"13734","DOI":"10.1038\/srep13734","article-title":"CRISPR\/Cas9 nickase-mediated disruption of hepatitis b virus open reading frame S and X","volume":"5","author":"Karimova","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.virol.2014.12.001","article-title":"Suppression of hepatitis b virus DNA accumulation in chronically infected cells using a bacterial CRISPR\/Cas RNA-guided DNA endonuclease","volume":"476","author":"Kennedy","year":"2015","journal-title":"Virology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1099\/vir.0.000159","article-title":"Inhibition of hepatitis b virus by the CRISPR\/Cas9 system via targeting the conserved regions of the viral genome","volume":"96","author":"Liu","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1038\/srep10833","article-title":"CRISPR\/Cas9 cleavage of viral DNA efficiently suppresses hepatitis b virus","volume":"5","author":"Ramanan","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.3748\/wjg.v21.i32.9554","article-title":"Dual gRNAs guided CRISPR\/Cas9 system inhibits hepatitis b virus replication","volume":"21","author":"Wang","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/gt.2015.2","article-title":"Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)\/crispr-associated Cas9 system to disrupt the hepatitis b virus","volume":"22","author":"Zhen","year":"2015","journal-title":"Gene Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/gtc.12437","article-title":"Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis b virus","volume":"21","author":"Sakuma","year":"2016","journal-title":"Genes Cells"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/mt.2016.94","article-title":"Complete spectrum of CRISPR\/Cas9-induced mutations on HBV cccDNA","volume":"24","author":"Seeger","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.virusres.2016.04.003","article-title":"CRISPR\/Cas9 produces anti-hepatitis b virus effect in hepatoma cells and transgenic mouse","volume":"217","author":"Zhu","year":"2016","journal-title":"Virus Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/cr.2017.16","article-title":"A non-viral CRISPR\/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo","volume":"27","author":"Jiang","year":"2017","journal-title":"Cell Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fcimb.2017.00091","article-title":"Removal of integrated hepatitis b virus DNA using CRISPR-Cas9","volume":"7","author":"Li","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1038\/s41598-017-07642-6","article-title":"Ssaavs containing cassettes encoding saCas9 and guides targeting hepatitis b virus inactivate replication of the virus in cultured cells","volume":"7","author":"Scott","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.7150\/thno.18114","article-title":"The gRNA-miRNA-gRNA ternary cassette combining CRISPR\/Cas9 with RNAi approach strongly inhibits hepatitis b virus replication","volume":"7","author":"Wang","year":"2017","journal-title":"Theranostics"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2018.02.011","article-title":"Inhibition of hepatitis b virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus","volume":"152","author":"Liu","year":"2018","journal-title":"Antiviral Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.omtn.2018.05.006","article-title":"One-vector system for multiplexed CRISPR\/Cas9 against hepatitis b virus cccDNA utilizing high-capacity adenoviral vectors","volume":"12","author":"Schiwon","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1002\/jcb.27050","article-title":"CRISPR\/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells","volume":"119","author":"Song","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nbt.2675","article-title":"Cas9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering","volume":"31","author":"Mali","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1086\/340041","article-title":"Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the united states, 1988-1994","volume":"185","author":"Xu","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.vetmic.2010.02.017","article-title":"Herpesviruses and immunity: The art of evasion","volume":"143","author":"Griffin","year":"2010","journal-title":"Vet. Microbiol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"van Diemen, F.R., and Lebbink, R.J. (2017). CRISPR\/Cas9, a powerful tool to target human herpesviruses. Cell. Microbiol., 19.","DOI":"10.1111\/cmi.12694"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrd1065","article-title":"Antiherpesvirus drugs: A promising spectrum of new drugs and drug targets","volume":"2","author":"Coen","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ijporl.2008.03.001","article-title":"A systematic review of the incidence of sensorineural hearing loss in neonates exposed to herpes simplex virus (HSV)","volume":"72","author":"Westerberg","year":"2008","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","article-title":"Herpes simplex virus infections","volume":"357","author":"Whitley","year":"2001","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12985-016-0600-9","article-title":"The mutated tegument protein ul7 attenuates the virulence of herpes simplex virus 1 by reducing the modulation of alpha-4 gene transcription","volume":"13","author":"Xu","year":"2016","journal-title":"Virol. J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"23146","DOI":"10.1038\/srep23146","article-title":"Inhibition of HSV-1 replication by gene editing strategy","volume":"6","author":"Roehm","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.coviro.2012.07.001","article-title":"Novel mechanisms of EBV-induced oncogenesis","volume":"2","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"13157","DOI":"10.1073\/pnas.1410785111","article-title":"Rna-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1099\/jgv.0.000012","article-title":"CRISPR\/Cas9-mediated genome editing of Epstein-Barr virus in human cells","volume":"96","author":"Yuen","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.virusres.2017.04.019","article-title":"Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR\/Cas9","volume":"244","author":"Yuen","year":"2018","journal-title":"Virus Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1172\/JCI45449","article-title":"Cytomegalovirus: Pathogen, paradigm, and puzzle","volume":"121","author":"Boeckh","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Gergen, J., Coulon, F., Creneguy, A., Elain-Duret, N., Gutierrez, A., Pinkenburg, O., Verhoeyen, E., Anegon, I., Nguyen, T.H., and Halary, F.A. (2018). Multiplex CRISPR\/Cas9 system impairs HCV replication by excising an essential viral gene. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0192602"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"van Diemen, F.R., Kruse, E.M., Hooykaas, M.J., Bruggeling, C.E., Schurch, A.C., van Ham, P.M., Imhof, S.M., Nijhuis, M., Wiertz, E.J., and Lebbink, R.J. (2016). CRISPR\/Cas9-mediated genome editing of herpesviruses limits productive and latent infections. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005701"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"612823","DOI":"10.1155\/2014\/612823","article-title":"Disruption of hpv16-e7 by CRISPR\/Cas system induces apoptosis and growth inhibition in hpv16 positive human cervical cancer cells","volume":"2014","author":"Hu","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"11965","DOI":"10.1128\/JVI.01879-14","article-title":"Inactivation of the human papillomavirus e6 or e7 gene in cervical carcinoma cells by using a bacterial CRISPR\/Cas RNA-guided endonuclease","volume":"88","author":"Kennedy","year":"2014","journal-title":"J. Virol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bbrc.2014.07.014","article-title":"In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR\/Cas9","volume":"450","author":"Zhen","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4103\/1008-682X.157399","article-title":"Reprogrammed CRISPR-Cas9 targeting the conserved regions of hpv6\/11 e7 genes inhibits proliferation and induces apoptosis in e7-transformed keratinocytes","volume":"18","author":"Liu","year":"2016","journal-title":"Asian J. Androl."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.tranon.2016.10.002","article-title":"In vitro and in vivo synergistic therapeutic effect of cisplatin with human papillomavirus16 e6\/e7 CRISPR\/Cas9 on cervical cancer cell line","volume":"9","author":"Zhen","year":"2016","journal-title":"Transl. Oncol."},{"key":"ref_102","first-page":"9206","article-title":"Deletion of hpv18 e6 and e7 genes using dual sgRNA-directed CRISPRCas9 inhibits growth of cervical cancer cells","volume":"10","author":"Yu","year":"2017","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2217\/fvl-2018-0010","article-title":"Targeting hpv16 DNA using CRISPR\/Cas inhibits anal cancer growth in vivo","volume":"13","author":"Hsu","year":"2018","journal-title":"Future Virol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.3949\/ccjm.78.s2.03","article-title":"The clinical features of PML","volume":"78","author":"Berger","year":"2011","journal-title":"Cleve Clin. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Wollebo, H.S., Bellizzi, A., Kaminski, R., Hu, W., White, M.K., and Khalili, K. (2015). CRISPR\/Cas9 system as an agent for eliminating polyomavirus JC infection. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136046"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/vr.103593","article-title":"Transmission routes of African swine fever virus to domestic pigs: Current knowledge and future research directions","volume":"178","author":"Guinat","year":"2016","journal-title":"Vet. Rec."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41598-018-19626-1","article-title":"Efficient inhibition of African swine fever virus replication by CRISPR\/Cas9 targeting of the viral p30 gene (cp204l)","volume":"8","author":"Hubner","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0147-9571(91)90128-Z","article-title":"Molecular biology of pseudorabies (aujeszky\u2019s disease) virus","volume":"14","author":"Mettenleiter","year":"1991","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.virusres.2016.08.001","article-title":"Pseudorabies virus can escape from CRISPR-Cas9-mediated inhibition","volume":"223","author":"Peng","year":"2016","journal-title":"Virus Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1007\/s00705-017-3553-4","article-title":"CRISPR\/Cas9-mediated multiple single guide RNAs potently abrogate pseudorabies virus replication","volume":"162","author":"Tang","year":"2017","journal-title":"Arch. Virol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature12048","article-title":"A CRISPR\/Cas system mediates bacterial innate immune evasion and virulence","volume":"497","author":"Sampson","year":"2013","journal-title":"Nature"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1073\/pnas.1422340112","article-title":"Cas9-mediated targeting of viral RNA in eukaryotic cells","volume":"112","author":"Price","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","article-title":"Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system","volume":"163","author":"Zetsche","year":"2015","journal-title":"Cell"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","article-title":"Non-viral delivery systems for CRISPR\/Cas9-based genome editing: Challenges and opportunities","volume":"171","author":"Li","year":"2018","journal-title":"Biomaterials"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/7\/1349\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:43:12Z","timestamp":1760186592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/7\/1349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":118,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["molecules24071349"],"URL":"https:\/\/doi.org\/10.3390\/molecules24071349","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,5]]}}}